RecruitingNCT07091526
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer
Sponsor
Hepatopancreatobiliary Surgery Institute of Gansu Province
Enrollment
168 participants
Start Date
Jul 29, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria3
- Patients with pathologically confirmed pancreatic cancer (primary)
- Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
- The postoperative survival time was at least 6 weeks
Exclusion Criteria14
- No surgery was performed, or only palliative surgery/ biopsy was performed
- Patients who underwent emergency hemodialysis or plasma exchange after surgery
- History of gout or long-term urate-lowering therapy, such as allopurinol
- Patients are missing follow-up data
- Hydrochlorothiazide and furosemide were used
- Chronic kidney disease
- Oncolytic syndrome
- Hemolytic anemia
- Lead poisoning
- Hyperparathyroidism
- Hypothyroidism
- A tyrosinase inhibitor was used
- Patients with nonpancreatic primary tumors
- Pregnant or postpartum women.
Interventions
DIAGNOSTIC_TESTserum uric acid test
Detect the serum uric acid in blood sample
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07091526